6-chloro-N-isopropyl-3-nitropyridin-2-amine | 27048-03-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 6-chloro-N-isopropyl-3-nitropyridin-2-amine
• 英文别名: 6-chloro-3-nitro-N-propan-2-ylpyridin-2-amine
• CAS: 27048-03-9
• 化学式: C₈H₁₀ClN₃O₂
• 分子量: 215.639
• InChiKey: BGSQZFPLKFOJHL-UHFFFAOYSA-N

物化性质

• 熔点：
  75-77 °C(Solvent: Methanol)
• 沸点：
  342.2±42.0 °C(Predicted)
• 密度：
  1.353±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-chloro-N-isopropyl-3-nitropyridin-2-amine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 氯化铵 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 甲苯 为溶剂， 反应 68.0h， 生成 N-(diphenylmethylene)-3-isopropyl-2-(4-(trifluoromethyl)benzyl)-3H-imidazo[4,5-b]pyridine-5-amine
  参考文献：
  名称：

  含氮双环化合物及其制备方法和用途

  摘要：

  本发明涉及一类含氮双环化合物及其制备方法和用途。所述化合物或药物组合物可作为维甲酸相关孤核受体γt(Retinoid‑related orphan receptor gamma t，RORγt)的抑制剂。本发明还涉及制备该类化合物和药物组合物的方法，以及它们在治疗或预防哺乳动物，特别是人类的由RORγt介导的炎症或自身免疫疾病的用途。

  公开号：

  CN108689942B
• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 异丙胺 以 乙醇 为溶剂， 反应 0.33h， 生成 6-chloro-N-isopropyl-3-nitropyridin-2-amine
  参考文献：
  名称：

  PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS

  摘要：

  本发明提供了I式化合物及其药学上可接受的盐类、酯类和前药，这些化合物是DGAT2抑制剂。同时，本发明提供了制备I式化合物的方法、含有I式化合物的制药组合物，以及使用这些化合物治疗肝脏脂肪变性、非酒精性脂肪性肝炎（NASH）、纤维化、2型糖尿病、肥胖症、高脂血症、高胆固醇血症、动脉硬化、认知下降、痴呆、心肾疾病如慢性肾脏疾病和心力衰竭等相关疾病和病症的方法，包括向需要治疗的患者投与I式化合物。

  公开号：

  US20220112182A1

文献信息

• Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones
  作者：Vassiliki Giannouli、Ioannis K. Kostakis、Nicole Pouli、Panagiotis Marakos、Pinelopi Samara、Ourania Tsitsilonis

  DOI：10.1016/j.bmcl.2015.04.093

  日期：2015.7

  A number of new substituted fused naphthyridinones has been prepared and their antiproliferative activity was evaluated against a panel of seven human tumor cell lines, including the variant MES-SA/Dx5, reported to be 100-fold resistant to doxorubicin. Certain derivatives exhibited interesting cytotoxic properties, possessing IC50 values in a low mu M range. (C) 2015 Published by Elsevier Ltd.
• Synthesis and Insecticidal Activity of Novel Nitropyridyl-Based Dichloropropene Ethers
  作者：Aiping Liu、Wanqi Yu、Minhua Liu、Jianjun Bai、Weidong Liu、Xingping Liu、Hui Pei、Li Hu、Mingzhi Huang、Xiaoguang Wang

  DOI：10.1021/acs.jafc.5b02279

  日期：2015.9.2

  Dihalopropene ether insecticides are known for good features such as no cross-resistance to other insecticide classes and safety for mammals. Pyridalyl is the only currently commercialized dichloropropene ether insecticide; however, it contains a trifluoromethyl group, the synthesis of which requires harsh reagents and reaction conditions. To search for novel dihalopropene ethers with unique biological activities but without trifluoromethyl groups, a series of nitropyridyl-based dichloropropene ether analogues were synthesized by reacting nitro-based halopyridine with 2,6-dichloro-4-(3,3-dichloroallyloxy)phenol or 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-hydroxypropyl ether. Bioassay showed that the compounds exhibited potent insecticidal activities against various lepidopteran pests. Particularly, 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-(5-nitro-2-pyridyloxy)propyl ether (8e) was active against major agricultural pests, and its insecticidal potency was comparable to that of Pyridalyl. Besides the trifluoromethyl group in Pyridalyl, a nitro group on the 5-position of the pyridyl ring is also viable for the development of optimal insecticidal activity.
• Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357
  作者：Christian Harcken、Johanna Csengery、Michael Turner、Lifen Wu、Shuang Liang、Robert Sibley、Steven Brunette、Mark Labadia、Kathleen Hoyt、Anita Wayne、Thomas Wieckowski、Gregg Davis、Mark Panzenbeck、Donald Souza、Stanley Kugler、Donna Terenzio、Delphine Collin、Dustin Smith、Ryan M. Fryer、Yin-Chao Tseng、Jörg P. Hehn、Kim Fletcher、Robert O. Hughes

  DOI：10.1021/acsmedchemlett.0c00575

  日期：2021.1.14